海外の治験の状況「1」での検索結果
379件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients with Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and are Treated with Insulin (ODYSSEY DM - Insulin)
- Hypercholesterolemia MedDRA version: 18.1 Level: LLT Classification code 10020604 Term: Hypercholesterolemia System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Austria, Finland, France, Germany, Greece, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States
- 2015-10-01
Authorised
- An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study)
- Non-small Cell Lung Cancer Tumors MedDRA version: 18.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIB System Organ Class: 100000004864 MedDRA version: 18.1 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States
- 2015-09-30
Authorised
- A study to compare an investigational ultra-rapid insulin, LY900014 with another mealtime insulin, Fiasp when both are used along with a long-acting insulin in people with type 1 diabetes
- Diabetes Mellitus, Type 1 MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Austria, Canada, Czech Republic, Germany, Romania, Spain, United Kingdom, United States
- 2018-11-23
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-09-12
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-08-22
Authorised
- This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, durvalumab given by itself or with tremelimumab versus sorafenib, the standard first line treatment, to treat patients with no prior systemic therapy for liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable).
- unresectable hepatocellular carcinoma (HCC) MedDRA version: 20.0 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Brazil, Canada, China, France, Germany, Hong Kong, India, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Thailand, Ukraine, United States, Vietnam
- 2017-09-06
Authorised
- A double-blind, placebo-controlled, three arm randomised multi-centre Gynaecologic Cancer InterGroup trial of AZD2171, in combination with platinum-based chemotherapy and as a single agent maintenance therapy, in women with ovarian cancer relapsing more than 6 months following completion of first line platinum-based treatment. - ICON6 GCIC Trial (International Collaborative Ovarian Neoplasm 6)
- epitehlial ovarian carcinoma, fallopian tube carcinoma, primary serous peritoneal carcinoma relapsing more than 6 months after completion of first-line platinum based chemotherapy br>MedDRA version: 14.1 Level: LLT Classification code 10033131 Term: Ovarian carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: LLT Classification code 10052171 Term: Peritoneal carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Australia, Canada, New Zealand, Spain, United Kingdom
- 2007-05-16
Authorised
- Phase III study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab in first line metastatic squamous NSCLC.
- metastatic squamous NSCLC MedDRA version: 20.0 Level: PT Classification code 10023775 Term: Large cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10001245 Term: Adenosquamous cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10001247 Term: Adenosquamous cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, China, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Russian Federation, Spain, Thailand, Turkey, United States
- 2016-04-26
Authorised
- Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)
- Transthyretin mediated amyloidosis (ATTR) MedDRA version: 17.1 Level: PT Classification code 10007509 Term: Cardiac amyloidosis System Organ Class: 10007541 - Cardiac disorders MedDRA version: 17.1 Level: PT Classification code 10019889 Term: Hereditary neuropathic amyloidosis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2015-03-03
Authorised
- A clinical study to determine the efficacy and safety of tisagenlecleucel, an investigational therapy, in first-line high-risk children and adolescent patients with B-cell acute lymphoblastic leukemia who are minimal residual disease positive at the end of consolidation therapy
- Pediatric and young adult patients aged 1 to 25 years with first-line NCI high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) who are in CR1 with minimal residual disease (MRD) positive (MRD = 0.01%) at the end of consolidation (EOC) therapy by central laboratory assessment. MedDRA version: 20.0 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom, United States
- 2018-07-27